Abstract: Lymphotoxin (LT) mutein (genetically-altered LT) is disclosed that has the following amino acid sequence, or a portion of an active portion of said protein, where 10 to 21 amino acids of LT being deleted from N-terminus and which has Pro or Phe at the N-terminus: ##STR1## Wherein R.sub.1 is Pro or Phe, R.sub.2 is a peptide chain represented by the following sequence:Ala-Gln-Thr-Ala-Arg-Gln-His-Pro-Lys-Met-His-Leu,or a portion thereof and n is 0 or 1.The LT mutein can be recovered in a higher yield and purified more efficiently under mild conditions which does not harm the LT's biological activity, than the whole LT.

Abstract: A compound of the formula: ##STR1## wherein R is a hydroxyl group which may be protected and Y is a purine base which may be protected, and the saltts thereof, which are useful as an antiviral agent.

Abstract: An animal cell line transformed with an expression vector for an animal cell, the expression vector which contains a DNA segment comprising:(a) a DNA sequence coding for a signal peptide of an animal cell-derived protein,(b) a second DNA sequence coding for a different protein from the signal protein joined downstream of said signal peptide encoding DNA sequence without causing any reading frame shift, and(c) a promoter DNA sequence capable of functioning in an animal cell, wherein the promoter sequence is positioned upstream of the signal peptide encoding DNA sequence, can produce glycosylated proteins advantageously as secretable proteins.

Abstract: Novel N.sup.2 -substituted-2,6-diaminonebularines of the formula: ##STR1## wherein R is 2-pyridyl or 3-pyridyl, which may be substituted, or acid addition salts thereof have an excellent coronary vasodilator action.

Abstract: Compounds of the formula ##STR1## wherein R is phenyl which may be substituted; or their acid addition salts, are produced in good yield by reacting a compound of the formula ##STR2## wherein R.sup.1, R.sup.2 and R.sup.3, independently of one another, are hydroxyl which may be protected, which is prepared in 2 or 3 steps from 5-amino-1-.beta.-D-ribofuranosylimidazole-4-carboxamide, with a compound of the formula ##STR3## wherein R has the same meaning as defined above and X is amino which may be substituted or lower alkylthio, and, if necessary subjecting the resulting compound to a treatment for removal of protective groups on its hydroxyls.

Abstract: Novel N.sup.2 -substituted phenyl-2,6-diaminonebularines of the formula ##STR1## wherein either one of R.sup.1 and R.sup.2 is carbamoyl which may be substituted or acyl group and the other is hydrogen atom, halogen atom or lower alkoxyl group, and their acid addition salts have an excellent coronary vasodilator action.

Abstract: Compounds of the formula ##STR1## wherein R is a phenyl or cyclohexyl group which may be substituted by halogen, lower alkyl or lower alkoxy, or their acid addition salts, are produced in good yield by reacting a compound of the formula ##STR2## wherein R.sup.1, R.sup.2 and R.sup.3, independently of each other, are a hydroxyl group which may be proctected, which is prepared in 2 or 3 steps from 5-amino-1-.beta.-D-ribofuranosylimidazole-4-carboxamide, with a compound of the formulaR--N.dbd.C.dbd.N--R.sup.4wherein R has the same meaning as defined above and R.sup.4 is hydrogen or the same group as R, and, if necessary, subjecting the resulting compound to a treatment for removal of protective groups on its hydroxyl groups.

Abstract: Novel N.sup.2 -substituted phenyl-2,6-diaminonebularines of the formula ##STR1## wherein R.sup.1 is halogen, lower alkyl or lower alkoxy and R.sup.2 is hydrogen, halogen, lower alkyl or lower alkoxy, and their acid addition salts have excellent coronary vasodilator action.

Abstract: Isoxazolo[3,4-d]pyrimidines of the formula ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3, respectively, are hydrogen, lower alkyl, cycloalkyl, or aryl which may be substituted by halogen, are useful as antiinflammatory-analgesic drugs, and the industrially feasible production thereof is provided.

Abstract: Novel 2,6-diaminonebularine derivatives of the formula ##SPC1##Wherein R is a phenyl or cyclohexyl group which may be substituted with lower alkyl, lower alkoxy or halogen, and pharmaceutically acceptable salts thereof, exhibit excellent pharmacological acitivity such as strong and prolonged coronary dilating and platelet aggregation inhibitory actions.